Sirtuins: The future insight

Kathmandu University Medical Journal

Volumn 10, Issue 38, 2012, Pages 77-82

  Suvarna, Beena S ^a  

^a MELAKA MANIPAL MEDICAL COLLEGE   (India)

Author keywords

Epigenetics; Histone deacetylases; SirT1 7; Sirtuins

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; EX 527; RESVERATROL; SALERMIDE; SIRTUIN; TENOVINS; UNCLASSIFIED DRUG; UV 15008;

AGING; ALZHEIMER DISEASE; APOPTOSIS; CARCINOGENESIS; CELL METABOLISM; CELL SURVIVAL; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LOCALIZATION; GERIATRIC DISORDER; GLIOMA; HUMAN; HUNTINGTON CHOREA; METABOLIC REGULATION; NEUROPROTECTION; NONHUMAN; PANCREAS CANCER; PARKINSON DISEASE; REVIEW;

EID: 84875959986     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: 10.3126/kumj.v10i2.7350     Document Type: Review

References (60)

1. Balcerczyk A, Pirols L. Therapeutic potential of activators and inhibitors of sirtuins. Biofactors. 2010; 36 (5):383-93.
2. Ahringer J. NuRD and SIN3 histone deacetylase complexes in development. Trends Genet. 2000; 16 (8): 351-56.
3. Alcain FJ, Villalba JM. Sirtuin inhibitors. Expert Opin Ther Pat.2009; 19(3): 283-94.
4. Dali-Youcef N, Lagouge M, Froelich S. Sirtuins: the magnificent seven, function, metabolism and longevity. Ann Med. 2007; 39(5):335-45.
5. Vaquero A. The conserved role of sirtuins in chromatin regulation. Int. J. Dev. Biol. 2009; 53:303-22.
6. Yamamoto H, Schoonjans K, Auwerx J. Sirtuin function in heath and disease. Mol. Endocrinol. 2007; 21(8):1745-55.
7. Marcia C, Leonard P, Guarente1. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes & Dev. 2006;20: 2913-21
8. Vassilopoulos A, Fritz KS, Dennis R., Petersen DR. The human sirtuin family: Evolutionary divergences and functions. Hum Genomics. 2011; 5(5): 485-96.
9. Dryden S.C., Nahhas F.A., Nowak J.E. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol. Cell. Biol.2003; 23(9):3173-85.
10. North B.J., Marshall BL., Borra M.T. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell. 2003; 11(2):437-444.
11. Michishita E., Park J.Y., Burneskis J.M. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell. 2005; 16 (10):4623-35.
12. Hiratsuka M., Inoue T., Toda T. Proteomics-based identification of differentially expressed genes in human gliomas: Down-regulation of SIRT2 gene. Biochem Biophys Res Commun. 2003; 309 (3):558-66.
13. Onyango P., Celic I., McCaffery J.M. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc. Natl. Acad. Sci. 2002; 99(21): 13653-58.
14. Schwer B., Bunkenborg J., Verdin R.O. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci. 2006; 103(27): 10224-29.
15. Shi T., Wang F., Stieren E., Tong, Q. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J Biol Chem. 2005; 280(14): 13560-567.
16. Hallows W.C., Lee S., Denu J.M. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci. 2006; 103(27): 10230-35.
17. Tsang A.W., Escalante-Semerena J.C. CobB, a new member of the SIR2 family of eucaryotic regulatory proteins, is required to compensate for the lack of nicotinate mononucleotide:5, 6-dimethylbenzimidazole phosphoribosyltransferase activity in cobT mutants during cobalamin biosynthesis in Salmonella typhimurium LT2. J Biol Chem. 1998; 273(48):31788-94.
18. Starai V.J., Celic I., Cole R.N. Sir2-dependent activation of acetyl-CoA synthetase by deacetylation of active lysine.Science.2002;298(5602):2390-92.
19. Haigis M.C., Mostoslavsky R., Haigis K.M. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic ß cells. Cell. 2006; 126 (5):941-54. http://www.ncbi.nlm.nih.gov/pubmed/16959573
20. Stanley C.A., Lieu Y.K., Hsu B.Y. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N. Engl. J. Med. 1998; 338(19):1352-57.
21. Nakagawa T, Guarente L. Urea cycle regulation by mitochondrial sirtuin, SIRT5. Aging. 2009;1(6): 578-81
22. Wallace, D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu Rev Genet.2005; 39:359-407. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821041/.
23. Michishita E, McCord RA, Berber E. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature. 2008;Mar 27: 452(7186):492-6.
24. Vakhrusheva O, Smolka C, Gajawada P. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res. 2008;102 (6): 703-10.
25. Ford E., Voit R., Liszt G.Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 2006; 20 (9):1075-1080.
26. McGuinness D, McGuinness DH, McCaul JA et al. Sirtuins, bioageing and cancer. J. Aging Res.2011; 235754.
27. Jiang WJ. Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun. 2008 Aug 29; 373(3):341-4.
28. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and Sir2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science.2009; 289: 2126-28.
29. Westphal CH, Dipp MA, Guarente L. A therapeutic role for sirtuins in diseases of aging? Trends Biochem Sci. 2007; 32 (12): 555-60.
30. Chua KF, Mostoslavsky R, Lombard DB. Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab. 2005; 2 (1):67-68.
31. Merce Pallas, Esther Verdaguer, Marta Tajes. Recent patents on CNS Drug Discovery. Bentham Science Publishers. Vol3, no.1, 2008. Pp.61-69 http://www.benthamscience.com/contents-JCode-PRN-Vol-00000003-Iss-00000001.htm.
32. Outiero TF, Marqes O, Kazantev A. Therapeutic role of sirtuins in neurodegenerative disease. Biochem Biophys Acta. 2008; 363-69.
33. Gao J, Wang WY, Mao YW. A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 2010; 466 (7310):1105-09.
34. Dohoon Kim, Minh Dang Nguyen, Matthew M Dobbin. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J. 2007 July 11; 26(13): 3169-3179. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1914106/.
35. Bouras T, Fu MF, Sauve AA. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. Journal of Biological Chemistry. 2005; 280:16456-60.
36. Haigas MC & Guarente LP. Mammalian sirtuins-emerging roles in physiology, aging and calorie restriction. Genes and Development. 2006; 20:2913-21.
37. Rodgers JT, Lerin C, Haas W. Nutrient control of glucose homeostasis through a complex of PGC-1 alpha and SIRT1. Nature 2005; 434:113-18.
38. Zhao WH, Kruse JP, Tang Y. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 2008; 451:587-90.
39. Ota H, Tokunaga E, Chang K. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signalling in human cancer cells. Oncogene. 2006b; 25:176-185.
40. Cohen HY, Lavu S, Bitterman KJ. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Molecular Cell 2004a; 13:627-38.
41. Deng CX. SirT1, is it a tumour promoter or tumour suppressor? Int J Biol Sci. 2009; 5(2): 147-152.
42. Bosch PL, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer.2011;2(6): 648-62.
43. Vaziri H, Dessain SK, Eaton E. hSIR2 (SIRT1) functions as an NAD-dependent p53 deacteylase. Cell. 2001; 107(2): 149-59.
44. Rahman S, Islam R. Mammalian Sirt1: insight on its biological functions. Cell Commun. Signal. 2011; 9: 11.
45. Firestein R, Blander G, Michan S. The sirt1 deacetylase suppress intestinal tumorigenesis and colon cancer growth. PLoS ONE. 2008. http://www.plosone.org/article/info:doi%2F10.1371%2Fjournal.pone.0002020
46. Wang RH, Sengupta K, Li C, Kim HS. Impaired DNA damage response, genome instability and tumorigenesis in SIRT1 mutant mice. Cancer cell. 2008;14(4): 312-23.
47. Kim HS, Patel K, Muldoon JK. SIRT3 is a mitochondria-localised tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell. 2010; 17(1): 41-52.
48. Ouaissi M, Sielezneff I, Silvestre R. High histone deacetylase 7 (HDAC7) expression is significantly associated is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol. 2008; 15(8):2318-28.
49. Vakhrusheva O, Braeuer D, Liu Z. Sirt7 dependent inhibiton of cell growth and proliferation might be instrumental to mediate tissue integrity during aging. J Physiol Pharmacol. 2008; 59 (suppl 9): 201-12.
50. Ashraf N, Zino S, Macintrye A. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer 2006; 95(8): 1056-61.
51. Liu T, Lui PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009; 69(5): 1702-05.
52. Lara E, Mai A, Calvanese V. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene. 2009; 28 (6): 781-91.
53. Grozinger CM, Chao ED, Blackwell HE. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylase s by phenotypic screening. J Biol Chem. 2001; 276(42): 38837-43.
54. Schuetz A, Min J, Antoshenko T. Structural basis of inhibition of the human NAD+ dependent deacetyalse SIRT5 by suramin. Structure. 2007;15(3): 377-89.
55. Trapp J, Meier R, Hongwiset D. Structure-activity studies on suramin analogues as inhibitors of NAD + dependent histone deacetylases (sirtuins). Chem Med Chem. 2007; 2(10): 1419-31.
56. Heltweg B, gatbonton T, Schuler A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res. 2006; 66 (8): 4368-77.
57. Lara S, Hollick JJ, Calvanese V. Salermide, a sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene. 2009; 28(6):781-91.
58. Solomon JM, Pasupuleti R, Xu L. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survivl following DNA damage. Mol Cell Biol Vol.2006; 26(1): 28-38.
59. Lain S, Hollick JJ, Campbell J. Discovery in vivo activity and mechansim of action of a small molecule p53 activator. Cancer Cell. 2008; 13(5): 454-63.
60. Nebbioso A, Pereira R, Khanwalkar H. Death receptor pathway activator and increase of ROS production by the triple epigenetic inhibitor, UV15008. Mol Cancer ther. 2011; 10(12): 2394-404.